CRDFNasdaq

Cardiff Oncology, Inc.

Biological Products, (No Diagnostic Substances) · DE · CIK 1213037

Developing novel cancer therapies by targeting PLK1 inhibition with onvansertib and standard treatments

red 8-K · 90d

$105M

Market cap

$1.27

Last close

+1.6%

-2.3%

945K

Volume

Price · last 39 sessions-23.0%

May 4L $1.18 · H $1.94Jun 29

564

Total filings

Jun 11, 2026

Last filing

12/31

Fiscal year end

Similar companies

Comparable business profile · signals at a glance